Welcome to our dedicated page for Arrowhead Pharma news (Ticker: ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Pharma stock.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) regularly issues news on its RNA interference (RNAi) pipeline, regulatory milestones, clinical data, and capital markets activity. This ARWR news page on Stock Titan aggregates those updates so readers can follow how the company’s gene-silencing therapeutics are progressing across cardiometabolic, obesity, and neurodegenerative indications.
Recent company announcements highlight approvals and regulatory actions for REDEMPLO (plozasiran), a small interfering RNA medicine targeting apoC-III for adults with familial chylomicronemia syndrome (FCS). Arrowhead has reported approvals for REDEMPLO in the United States, Canada, and China, as well as Breakthrough Therapy designation for investigational plozasiran in severe hypertriglyceridemia and ongoing Phase 3 trials in broader triglyceride disorders.
News items also cover interim clinical data for investigational obesity candidates ARO-INHBE and ARO-ALK7, which the company is studying for effects on visceral fat, total fat, liver fat, and body weight, including in obese patients with type 2 diabetes mellitus. Additional coverage includes the initiation of a Phase 1/2a study of ARO-MAPT for tauopathies such as Alzheimer’s disease, using a TRiM-based delivery system intended to reach the central nervous system after subcutaneous administration.
Investors and observers will also find Arrowhead’s press releases on public offerings of common stock, pre-funded warrants, and 0.00% convertible senior notes due 2032, as well as collaboration and licensing updates such as the agreement with Novartis for ARO-SNCA and arrangements involving Visirna Therapeutics and Sanofi in Greater China. Bookmark this page to review Arrowhead’s earnings-related 8-K references, conference participation, and ongoing disclosures about its RNAi programs and commercial activities.
FAQ
What is the current stock price of Arrowhead Pharma (ARWR)?
What is the market cap of Arrowhead Pharma (ARWR)?
